Clinical applications of C18 and C20 chain length polyunsaturated fatty acids and their biotechnological production in plants.

摘要

A potential revolution in FA therapies is on the horizon. In recent years, the full magnitude of various FA treatments and their overall importance to health has become increasingly apparent. Fetal and infant nutrition studies have clearly shown that FA status at birth can have life-long health implications affecting eye and brain function, insulin resistance, and blood pressure control. As well, nutrition studies have identified dietary imbalances and deficiencies that have the potential to alter the health of future generations severely and to promote progression of age-related degenerative disorders. Mixtures of naturally occurring FA have shown promise as therapeutic agents for a diverse range of health conditions including atopic eczema, rheumatoid arthritis, cardiovascular disease, and neurological problems. Through the 1990s, the creation of technologies to concentrate and formulate pharmacologically active individual FA components as well as tailored combinations propelled development of this new drug category. However, high production costs and government regulatory encumbrance limited the expansion of this emerging pharmaceutical sector. Fortunately, many countries are now creating regulatory frameworks that are better suited for product evaluation and control of the manufacturing FA products than historical drug models, and hence expansion in this area is now anticipated..